Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Eligibility

DG Desye Gebrie
DG Desalegn Getnet
TM Tsegahun Manyazewal
request Request a Protocol
ask Ask a question
Favorite

We formulated the study’s eligibility criteria using the PICOS (participants, interventions, comparison, outcomes, and study designs) description model44:

Participants

Patients with T2DM

Man or woman of any age

Who was taking a combination therapy of metformin-sulfonylurea or metformin-SGLT2Is

Intervention

A combination of metformin with any of the SGLT2Is, which could be dapagliflozin, canagliflozin, empagliflozin, or ertugliflozin.

Comparator

A combination of metformin with any of sulfonylureas compounds, which could be gliclazide, glipizide, glyburide, glibenclamide, or glimepiride.

Outcomes

Primary endpoints

All-cause mortality

Serious adverse events (SAEs).

Secondary endpoints

Cardiovascular mortality

Non-fatal myocardial infarction

Non-fatal stroke

Hypoglycemia

Changes in HbA1c

Change in body weight,

Changes in fasting plasma glucose (FPG)

Changes in systolic blood pressure (SBP

Changes in diastolic blood pressure (DBP)

Changes in low-density lipoprotein cholesterol (LDL-C)

Changes in high-density lipoprotein cholesterol (HDL-C)

Study design

RCTs

At least one-year duration of follow-up

Published in English language

Copyright and License information: The Author(s) ©2021
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A